Concentration Of Risk	9 Months Ended
Sep. 30, 2020
Concentration Of Risk [Abstract]
Concentration Of Risk	12. Concentration of Risk As of September 30, 2020, and December 31, 2019, approximately 67% and 71%, respectively, of VITAS’ total accounts receivable balance were from Medicare and 26% and 24%, respectively, of VITAS’ total accounts receivable balance were due from various state Medicaid or managed Medicaid programs. Combined accounts receivable from Medicare, Medicaid, and managed Medicaid represent approximately 80% of the consolidated net accounts receivable in the accompanying consolidated balance sheets as of September 30, 2020. VITAS has a pharmacy services contract with one service provider for specified pharmacy services related to its hospice operations. A large majority of VITAS’ pharmaceutical purchases are from this vendor. The pharmaceuticals purchased by VITAS are available through many providers in the United States. However, a disruption from VITAS’ main service provider could adversely impact VITAS’ operations, including temporary logistical challenges and increased cost associated with getting medication to our patients.

Concentration Of Risk

9 Months Ended

Sep. 30, 2020

12. Concentration of Risk

As of September 30, 2020, and December 31, 2019, approximately 67% and 71%, respectively, of VITAS’ total accounts receivable balance were from Medicare and 26% and 24%, respectively, of VITAS’ total accounts receivable balance were due from various state Medicaid or managed Medicaid programs. Combined accounts receivable from Medicare, Medicaid, and managed Medicaid represent approximately 80% of the consolidated net accounts receivable in the accompanying consolidated balance sheets as of September 30, 2020.

VITAS has a pharmacy services contract with one service provider for specified pharmacy services related to its hospice operations. A large majority of VITAS’ pharmaceutical purchases are from this vendor. The pharmaceuticals purchased by VITAS are available through many providers in the United States. However, a disruption from VITAS’ main service provider could adversely impact VITAS’ operations, including temporary logistical challenges and increased cost associated with getting medication to our patients.